Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arthitec 1 and Arthitec 2 in Arthritis
NCT03506919Phase 2Unknown
- Sponsor
- Shifa-ul-Mulk Memorial Hospital
- Start
- Jan 2018
- Primary completion
- Apr 2018
- Countries
- 1
01
Overview
Phase 2, randomised trial (2 arms), sponsored by Shifa-ul-Mulk Memorial Hospital. Primary endpoint: Reduction in Serum Uric Acid level at 8 weeks. Status: unknown.
Beyond the preview
Go deeper on NCT03506919.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506919.